Issue 154

Bringing psychedelics to mainstream education

The University of Exeter, UK, has launched the world’s first post-graduate course on psychedelics. Psychedelic Health speaks to Dr Peter Sjöstedt-Hughes about what the course involves and the significance of psychedelics entering mainstream academia.

“We introduced this course because it didn’t exist. For the last 50 years, we’ve had propaganda against psychedelics. Much of that turns out to be false,” says Dr Sjöstedt-Hughes.

“For a Russell Group University to endorse this course, and to have research in two departments, is mainstream acceptance, which is important.”

He went on to say: “…with this Psychedelic Renaissance, it’s streamlined through the medical framework. With that framework, there comes many ethical questions—and ethics, of course, is the purview of philosophy. So, it’s important to have a critical analysis of what’s going on from an academic point of view.”



A report has revealed that the consumption of ayahuasca is increasing in several countries.

Published by Carlos Suárez Álvarez and the International Center for Ethnobotanical Education, Research and Service (ICEERS), the report documents ayahuasca use across the Netherlands, Spain, the USA and Colombia.

Read More


Drug Science has launched a new consultancy arm with an emphasis on the emerging cannabis and psychedelic medicine markets.

CEO of Drug Science, Dr Anne Katrin Schlag, stated:  “Drug Science Consultancy will allow us to work closely together with clients who are keen to develop, conduct, and analyse their own high-quality scientific research — which is what we love doing.”

Read More


Awakn Life Sciences has confirmed it has now engaged Orphan Insight Ltd. to advance market access, pricing, and reimbursement strategies for AWKN-P001.

Cannabis and psychedelics industry pioneer, Ronan Levy, has been appointed as President of investment company Safe Supply Streaming Co Ltd.

Enveric Biosciences has confirmed it has received an NoA from USPTO for a patent application involving its new chemical entity (NCE) prodrug of psilocin.

Beckley Waves has announced it has acquired ketamine-assisted therapy provider, Nue Life, and will continue its work with a focus on underserved areas.

Would your organisation benefit from engaging Europe's psychedelic medicine community?

Partnership with Psychedelic Health provides the opportunity to engage an audience ready to support the development of psychedelic medicine.

For more information and to request the media kit, please email



New findings have shown the safety and effectiveness of continuous IV DMT administration, laying the “groundwork for the further development of this method of administration for basic and clinical research.”

Mind Medicine has completed enrollment in its Phase 2a study evaluating repeated low-dose administration of MM-120 (LSD) for the treatment of adults with ADHD.

A systematic review – Pharmacological Interaction of Compounds in Ayahuasca – has sought to better understand what components are essential in Ayahuasca, how they interact, and more.

Cybin has announced Phase 2 interim results for CYB003, which demonstrate a “rapid, robust and statistically significant reduction in symptoms of depression.”


Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses.

The Australian Capital Territory has now decriminalised the possession of small amounts of certain illegal drugs including MDMA, LSD and psilocybin.

The DEA has called for an increase in the production of certain psychedelic compounds including psilocybin and psilocin to meet demands.

Missoula Current reports that a federal appeals court panel has revived a petition to reschedule psilocybin from Schedule I to Schedule II status.


Community pharmacies in Scotland will now hold Naloxone kits which can be used to reverse opioid overdoses.

The UK has announced £100 million investment that is earmarked for AI in healthcare, including in mental health.